Navigation Links
Genetic study confirms: First dogs came from East Asia
Date:11/23/2011

the only -- region for wolf domestication, and that a large number of wolves were domesticated", says Savolainen.

In separate research published recently in Ecology and Evolution, Savolainen, PhD student Arman Ardalan and Iranian and Turkish scientists conducted a comprehensive study of mitochondrial DNA , with a particular focus on the Middle East. Because mitochondrial DNA is inherited only from the mother in most species, it is especially useful in studying evolutionary relationships.

"Since other studies have indicated that wolves were domesticated in the Middle East, we wanted to be sure nothing had been missed. We find no signs whatsoever that dogs originated there", says Savolainen.

In their studies, the researchers also found minor genetic contributions from crossbreeding between dogs and wolves in other geographic regions, including the Middle East.

"This subsequent dog/wolf hybridisation contributed only modestly to the dog gene pool", Savolainen explains.


'/>"/>
Contact: Katarina Ahlfort
press@kth.se
46-734-618-189
Swedish Research Council
Source:Eurekalert

Page: 1 2

Related biology news :

1. Rare genetic disorder gives clues to autism, epilepsy, mental retardation
2. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
3. Study finds genetic variant plays role in cleft lip
4. Genetic finding implicates innate immune system in major cause of blindness
5. American College of Medical Genetics receives $13.5M NIH contract
6. Clue to genetic cause of fatal birth defect
7. Can genetic information be controlled by light?
8. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
9. Modern genetics vs. ancient frog-killing fungus
10. Genetic based human diseases are an ancient evolutionary legacy
11. Genetic evidence for avian influenza movement from Asia to North America via wild birds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
(Date:7/10/2014)...  Unisys Corporation,s (NYSE: UIS ) subsidiary in ... announced that it has been selected by the Dutch Custodial ... Basic Provision Biometrics solution for penitentiaries across The ... with a solution based on its open standards-based LEIDA ... contract is up to seven years, with the new system ...
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... in his thesis that streams and lakes of Northern Sweden ... the atmosphere. Erik defends his findings at Sweden,s Ume University ... this study accounted for only about four percent of the ... releasing about ten times as much carbon as lakes," says ...
... and Drug Administration (FDA) mandates adequate enrollment of women in ... sex differences in device safety and effectiveness are not overlooked. ... of a study evaluating the participation of women and analysis ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers ...
... developed efficiency in the biomass supply and use for ... Energy and Environment Partnership Programme of the Ministry for ... working phases reduce transport costs by 15%. The production ... demonstrated to be financially and technologically sound. , Vietnam ...
Cached Biology News:Arctic inland waters emit large amounts of carbon 2Biomass supply chains developed by VTT speed up use of bioenergy in Vietnam 2
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
... of Hepatitis C Patients Is Skewed Towards Medicare ... in the General Population, According to a New ... Decision Resources, one of the world,s leading ... healthcare issues, finds that hepatitis C virus patient ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) announced ... for the Riquent(R) Phase 3 ASPEN trial, the ... of the trial is,futile. BioMarin and partner ... unblind the data and evaluate all of the ...
Cached Biology Technology:SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 2Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets 3Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3